Advances in Targeting Signal Transduction Pathways

ECU Author/Contributor (non-ECU co-authors, if there are any, appear on document)

Jörg Bäsecke (Creator)

Melchiorre Cervello (Creator)

Zoya N. Demidenko (Creator)

Lyudmyla Drobot (Creator)

Joanna Dulińska-Litewka (Creator)

Danijela Maksimovic-Ivanic (Creator)

Sanja Mijatovic (Creator)

Michele Milella (Creator)

Giuseppe Montalto (Creator)

Jerry Polesel (Creator)

Agostino Tafuri (Creator)

Renato Talamini (Creator)

Kazuo Umezawa (Creator)

Institution

East Carolina University (ECU )

Web Site: http://www.ecu.edu/lib/

Abstract: Extracted text; Over the past few years, significant advances have occurred in both our understanding of the complexity of signal transduction pathways as well as the isolation of specific inhibitors which target key components in those pathways. Furthermore critical information is being accrued regarding how genetic mutations can affect the sensitivity of various types of patients to targeted therapy. Finally, genetic mechanisms responsible for the development of resistance after targeted therapy are being discovered which may allow the creation of alternative therapies to overcome resistance. This review will discuss some of the highlights over the past few years on the roles of key signaling pathways in various diseases, the targeting of signal transduction pathways and the genetic mechanisms governing sensitivity and resistance to targeted therapies.

Additional Information

Publication

Other

Oncotarget; 3:12 p. 1505-1521

Language: English

Date: 2012

Keywords

mTOR, Metformin, Targeted Therapy, Cancer Stem Cells, Raf, Akt, Therapy Resistance, AMPK, PI3K

Email this document to